|
|
Blood, 15 June 2006, Vol. 107, No. 12, pp. 4628-4635.
Prepublished online as a Blood First Edition Paper on February 23, 2006; DOI 10.1182/blood-2005-11-4370.
Previous Article | Table of Contents | Next Article 
CLINICAL TRIALS AND OBSERVATIONS
The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy
Philip S. Rosenberg,
Blanche P. Alter,
Audrey A. Bolyard,
Mary Ann Bonilla,
Laurence A. Boxer,
Bonnie Cham,
Carol Fier,
Melvin Freedman,
George Kannourakis,
Sally Kinsey,
Beate Schwinzer,
Connie Zeidler,
Karl Welte,
David C. Dale, for the Severe Chronic Neutropenia International Registry
From the Biostatistics Branch and Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, MD; Department of Medicine, University of Washington, Seattle, WA; Department of Pediatric Hematology Oncology, St Joseph's Children's Hospital, Paterson, NJ; Department of Pediatrics, University of Michigan Medical Center, Ann Arbor, MI; CancerCare Manitoba, Winnipeg, MB, Canada; Amgen, Inc, Boulder, CO; Hospital for Sick Children, Toronto, ON, Canada; Ballarat Oncology and Haemotology Services, Wendouree, Australia; St James's University Hospital, Leeds, United Kingdom; and Kinderklinik, Medizinische Hochschule, Hannover, Germany.
In patients with severe congenital neutropenia (SCN), sepsis mortality is reduced by treatment with granulocyte colony-stimulating factor (G-CSF), but myelodsyplastic syndrome and acute myeloid leukemia (MDS/AML) have been reported. We studied 374 patients with SCN and 29 patients with Shwachman-Diamond syndrome (SDS) on long-term G-CSF enrolled in the Severe Chronic Neutropenia International Registry. In SCN, sepsis mortality was stable at 0.9% per year. The hazard of MDS/AML increased significantly over time, from 2.9% per year after 6 years to 8.0% per year after 12 years on G-CSF. After 10 years, the cumulative incidence was 8% for sepsis mortality and 21% for MDS/AML. A subgroup of SCN patients (29%) received more than the median dose of G-CSF ( 8 µg/kg/d), but achieved less than the median absolute neutrophil count (ANC) response (ANC < 2.188 x 109/L [2188/µL] at 6-18 months). In these less-responsive patients, the cumulative incidence of adverse events was highest: after 10 years, 40% developed MDS/AML and 14% died of sepsis, compared with 11% and 4%, respectively, of more responsive patients whose ANC was above the median on doses of G-CSF below the median. Risk of MDS/AML may be similar in SDS and SCN. In less-responsive SCN patients, early hematopoietic stem cell transplantation may be a rational option.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
Related Article in Blood Online:
-
Reconsidering how we treat severe congenital neutropenia
- Kevin Shannon
Blood 2006 107: 4575-4576.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
K. Beel and P. Vandenberghe
G-CSF receptor (CSF3R) mutations in X-linked neutropenia evolving to acute myeloid leukemia or myelodysplasia
Haematologica,
October 1, 2009;
94(10):
1449 - 1452.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Czader and A. Orazi
Therapy-Related Myeloid Neoplasms
Am J Clin Pathol,
September 1, 2009;
132(3):
410 - 425.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. P. Alter, N. Giri, S. A. Savage, and P. S. Rosenberg
Cancer in dyskeratosis congenita
Blood,
June 25, 2009;
113(26):
6549 - 6557.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Gurion, A. Gafter-Gvili, M. Paul, L. Vidal, I. Ben-Bassat, M. Yeshurun, O. Shpilberg, and P. Raanani
Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy-systematic review and meta-analysis
Haematologica,
May 1, 2009;
94(5):
712 - 719.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. Pulsipher, P. Chitphakdithai, J. P. Miller, B. R. Logan, R. J. King, J. D. Rizzo, S. F. Leitman, P. Anderlini, M. D. Haagenson, S. Kurian, et al.
Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program
Blood,
April 9, 2009;
113(15):
3604 - 3611.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Germeshausen, K. Welte, and M. Ballmaier
In vivo expansion of cells expressing acquired CSF3R mutations in patients with severe congenital neutropenia
Blood,
January 15, 2009;
113(3):
668 - 670.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Boztug, G. Appaswamy, A. Ashikov, A. A. Schaffer, U. Salzer, J. Diestelhorst, M. Germeshausen, G. Brandes, J. Lee-Gossler, F. Noyan, et al.
A Syndrome with Congenital Neutropenia and Mutations in G6PC3
N. Engl. J. Med.,
January 1, 2009;
360(1):
32 - 43.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. A. Boxer, A. A. Bolyard, P. E. Newburger, M. A. Bonilla, G. Kannourakis, Y. Dror, D. C. Link, B. P. Alter, P. S. Rosenberg, and D. C. Dale
Risk for Septic Death in Severe Congenital Neutropenia
Blood (ASH Annual Meeting Abstracts),
November 16, 2008;
112(11):
3548 - 3548.
[Abstract]
|
 |
|

|
 |

|
 |
 
M. Jadersten, L. Malcovati, I. Dybedal, M. Giovanni Della Porta, R. Invernizzi, S. M. Montgomery, C. Pascutto, A. Porwit, M. Cazzola, and E. Hellstrom-Lindberg
Erythropoietin and Granulocyte-Colony Stimulating Factor Treatment Associated With Improved Survival in Myelodysplastic Syndrome
J. Clin. Oncol.,
July 20, 2008;
26(21):
3607 - 3613.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. W. Robinson, N.-K. V. Cheung, C. P. Kolaris, S. C. Jhanwar, J. K. Choi, N. Osheroff, and C. A. Felix
Prospective tracing of MLL-FRYL clone with low MEIS1 expression from emergence during neuroblastoma treatment to diagnosis of myelodysplastic syndrome
Blood,
April 1, 2008;
111(7):
3802 - 3812.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J Townshend, J Clark, A Cant, P Carey, P Kumar, and D Campbell
Congenital neutropenia
Arch. Dis. Child. Ed. Pract.,
February 1, 2008;
93(1):
14 - 18.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. M. R. Choi, C. Guelcher, and M. F. Guerrera
Novel treatment for severe congenital neutropenia with pegfilgrastim
Blood,
December 1, 2007;
110(12):
4134 - 4134.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Badolato, M. Donini, G. Savoldi, and S. Dusi
Response: ELA2 genotype-phenotype correlation to be expected in patients with severe congenital neutropenia
Blood,
October 1, 2007;
110(7):
2773 - 2774.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. C. Link, G. Kunter, Y. Kasai, Y. Zhao, T. Miner, M. D. McLellan, R. E. Ries, D. Kapur, R. Nagarajan, D. C. Dale, et al.
Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia
Blood,
September 1, 2007;
110(5):
1648 - 1655.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Donini, S. Fontana, G. Savoldi, W. Vermi, L. Tassone, F. Gentili, E. Zenaro, D. Ferrari, L. D. Notarangelo, F. Porta, et al.
G-CSF treatment of severe congenital neutropenia reverses neutropenia but does not correct the underlying functional deficiency of the neutrophil in defending against microorganisms
Blood,
June 1, 2007;
109(11):
4716 - 4723.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. P. Alter and P. S. Rosenberg
Granulocyte colony-stimulating factor and severe aplastic anemia
Blood,
May 15, 2007;
109(10):
4589 - 4589.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. G. Blanchard and S. J. Corey
Filgrastim therapy: a bone of contention
Blood,
April 15, 2007;
109(8):
3125 - 3126.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Socie, J.-Y. Mary, H. Schrezenmeier, J. Marsh, A. Bacigalupo, A. Locasciulli, M. Fuehrer, A. Bekassy, A. Tichelli, and J. Passweg
Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT)
Blood,
April 1, 2007;
109(7):
2794 - 2796.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. S. Horwitz, Z. Duan, B. Korkmaz, H.-H. Lee, M. E. Mealiffe, and S. J. Salipante
Neutrophil elastase in cyclic and severe congenital neutropenia
Blood,
March 1, 2007;
109(5):
1817 - 1824.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. P. Touw and M. Bontenbal
Granulocyte Colony-Stimulating Factor: Key (F)actor or Innocent Bystander in the Development of Secondary Myeloid Malignancy?
J Natl Cancer Inst,
February 7, 2007;
99(3):
183 - 186.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Hershman, A. I. Neugut, J. S. Jacobson, J. Wang, W.-Y. Tsai, R. McBride, C. L. Bennett, and V. R. Grann
Acute Myeloid Leukemia or Myelodysplastic Syndrome Following Use of Granulocyte Colony-Stimulating Factors During Breast Cancer Adjuvant Chemotherapy
J Natl Cancer Inst,
February 7, 2007;
99(3):
196 - 205.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. P. Alter
Diagnosis, Genetics, and Management of Inherited Bone Marrow Failure Syndromes
Hematology,
January 1, 2007;
2007(1):
29 - 39.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. C. Link and T. Wun
Myeloid disorders
ASH Self-Assessment Program,
January 1, 2007;
2007(1):
143 - 171.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Germeshausen, M. Ballmaier, and K. Welte
Incidence of CSF3R mutations in severe congenital neutropenia and relevance for leukemogenesis: results of a long-term survey
Blood,
January 1, 2007;
109(1):
93 - 99.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Ferretti, P. Papaldo, F. Cognetti, D. C. Dale, P. S. Rosenberg, B. P. Alter, and K. Kaushansky
Lineage-specific hematopoietic growth factors.
N. Engl. J. Med.,
August 3, 2006;
355(5):
526 - 527.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. E. Newburger
Disorders of Neutrophil Number and Function
Hematology,
January 1, 2006;
2006(1):
104 - 110.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|